Advertisement

Breast Cancer Research and Treatment

, Volume 44, Issue 3, pp 211–215 | Cite as

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

  • Carol A. Sawka
  • Kathleen I. Pritchard
  • Wendy Shelley
  • Gerrit DeBoer
  • Alexander H.G. Paterson
  • J. William Meakin
  • Donald J.A. Sutherland
Article

Abstract

We concluded a randomized crossover trial comparing tamoxifen 40 mg daily with ovarian ablation for treatment of metastatic breast cancer in premenopausal women. Objective responses (complete response (CR) plus partial response (PR)) were observed in 5/20 patients treated initially with tamoxifen and in 3/19 patients initially treated with ovarian ablation (p=0.69). Seven additional patients were stable (SD) on tamoxifen while five additional patients were stable after ovarian ablation, for CR + PR + SD rates of 12/20 (60%) for tamoxifen and 8/19 (42%) for ovarian ablation (p=0.34). Median time to disease progression was 184 days for tamoxifen and 126 days for ovarian ablation (p=0.40, logrank test, odds ratio for progression 0.71). Overall survival times were also similar: a median of 2.35 years for tamoxifen and 2.46 years for ovarian ablation (p=0.98, logrank test, odds ratio for death 1.07). Side effects from tamoxifen included hot flashes and menstrual abnormalities. With one exception, these toxicities were not sufficient to require dose reduction. In this small study, tamoxifen was associated with similar response rates, response durations, and survival times to those observed with ovarian ablation.

metastatic breast cancer premenopausal women ovarian ablation tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fracchia AA, Farrow JH, DePalo AJ, Connolly DP, Huvos AG: Castration for primary inoperable or recurrent breast cancer. Surg Gynecol Obstet 128: 1226-1234, 1969PubMedGoogle Scholar
  2. 2.
    Dao TL: Ablation therapy for hormone-dependent tumors. Annu Rev Med 23: 1-18, 1972PubMedGoogle Scholar
  3. 3.
    McGuire WL: Endocrine therapy of breast cancer. Annu Rev Med 26: 353-363, 1975PubMedGoogle Scholar
  4. 4.
    Oriana S, Secreto G, Severini A, Di Fronzo G, Di Giuseppe M, Valagussa P, Preda F: Bilateral ovariectomy in premenopausal patients with advanced breast cancer, after the evaluation of estrogen receptor and urinary androgen excretion. Breast Cancer Res Treat 2: 101-104, 1982PubMedGoogle Scholar
  5. 5.
    Pritchard K, Thomson DB, Myers RE, Sutherland DJ, Mobbs BG, Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787-795, 1980PubMedGoogle Scholar
  6. 6.
    Heuson J-C: Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep 60: 1431-1435, 1976PubMedGoogle Scholar
  7. 7.
    Manni A, Pearson OH: Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: Effects on ovarian function. Cancer Treat Rep 64: 779-785, 1980PubMedGoogle Scholar
  8. 8.
    Wada T, Koyama H, Terasawa KT: Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65: 728-729, 1981PubMedGoogle Scholar
  9. 9.
    Yoshida M, Murai M, Miura S: Tamoxifen therapy for premenopausal and postmenopausal Japanese females with advanced breast cancer. Jpn J Clin Oncol 12: 57-64, 1982Google Scholar
  10. 10.
    Hoogstraten KB, Fletcher WS, Gad-el-Mawla N, Maloney T, Altman SJ, Vaughn CB, Foulkes MA: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 42: 4788-4791, 1982PubMedGoogle Scholar
  11. 11.
    Margreiter R, Wiegele J: Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treat 4: 45-48, 1984PubMedGoogle Scholar
  12. 12.
    Planting AST, Alexieva-Figusch J, Blonk-van der Wijst J, van Putten WLI: Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69: 363-368, 1985PubMedGoogle Scholar
  13. 13.
    Sawka CA, Pritchard KI, Paterson AHG, Sutherland DJ, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46: 3152-3156, 1986PubMedGoogle Scholar
  14. 14.
    Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178-185, 1986PubMedGoogle Scholar
  15. 15.
    Breast Cancer Task Force, Treatment Committee, National Cancer Institute. Breast Cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials, (NIH) 77-1192, Washington DC: Department of Health, Education and WelfareGoogle Scholar
  16. 16.
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc J 53: 457-481, 1958Google Scholar
  17. 17.
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977PubMedGoogle Scholar
  18. 18.
    Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326-1330, 1986PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Carol A. Sawka
    • 1
    • 2
    • 3
  • Kathleen I. Pritchard
    • 1
    • 2
    • 3
  • Wendy Shelley
    • 4
  • Gerrit DeBoer
    • 1
    • 2
    • 5
  • Alexander H.G. Paterson
    • 6
  • J. William Meakin
    • 2
  • Donald J.A. Sutherland
    • 1
    • 2
    • 3
  1. 1.Toronto Sunnybrook Regional Cancer CentreTorontoCanada
  2. 2.Ontario Cancer Treatment and Research Foundation (OCTRF)TorontoCanada
  3. 3.Department of MedicineUniversity of TorontoTorontoCanada
  4. 4.Kingston Regional Cancer Centre, OCTRF, and Queen's UniversityKingstonCanada
  5. 5.Departments of Medical Biophysics & Preventive Medicine and BiostatisticsUniversity of TorontoCanada
  6. 6.Tom Baker Cancer CentreAlberta Cancer Board and the University of CalgaryCalgaryCanada

Personalised recommendations